Mp57-02 Out-of-Pocket Costs Downstream of Prostate Cancer Screening Among Privately Insured Men

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Out‐of‐pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men2024 · 4 citations
2. 2MP68-13 TRENDS AND PREDICTORS OF MRI-GUIDED BIOPSY FOR PROSTATE CANCER DIAGNOSIS IN THE UNITED STATES2024
3. 3MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM2024
4. 4PD08-12 WHAT THE PRICE TRANSPARENCY FINAL RULE TEACHES US ABOUT SEX-SPECIFIC SERVICES: LOW COMPLIANCE AND REGIONAL VARIABILITY IN MALE UROLOGICAL PROCEDURES2024
5. 5MP70-12 ACTIVE SURVEILLANCE AND CONFIRMATORY TESTING AMONG MEDICAID PATIENTS: RESULTS FROM THE MICHIGAN UROLOGICAL SURGERY IMPROVEMENT COLLABORATIVE2024